Adjuvant Targeted Immunotherapy Offers Short-Term Benefits for Resectable Hepatocellular Carcinoma But May Increase Late Recurrence Risk: Comparative Insights From the CARES-009 and IMbrave050 Trials

Shuanggang Chen; Lujun Shen; Letao Lin; Han Qi; Fei Cao; Lin Xie; Yujia Wang; Ruizhi Tang; Chen Li; Weijun Fan

doi:10.1002/mog2.70089

MEDCOMM - Oncology ›› 2026, Vol. 5 ›› Issue (3) :e70089 DOI: 10.1002/mog2.70089

LETTER

Adjuvant Targeted Immunotherapy Offers Short-Term Benefits for Resectable Hepatocellular Carcinoma But May Increase Late Recurrence Risk: Comparative Insights From the CARES-009 and IMbrave050 Trials

Shuanggang Chen ¹^,²
, Lujun Shen ¹^,²
, Letao Lin ¹^,²
, Han Qi ¹^,²
, Fei Cao ¹^,²
, Lin Xie ¹^,²
, Yujia Wang ¹^,²
, Ruizhi Tang ¹^,²
, Chen Li ¹^,²
, Weijun Fan ¹^,²

Author information +

History +

PDF (223KB)

Cite this article

Download citation ▾

Shuanggang Chen, Lujun Shen, Letao Lin, Han Qi, Fei Cao, Lin Xie, Yujia Wang, Ruizhi Tang, Chen Li, Weijun Fan. Adjuvant Targeted Immunotherapy Offers Short-Term Benefits for Resectable Hepatocellular Carcinoma But May Increase Late Recurrence Risk: Comparative Insights From the CARES-009 and IMbrave050 Trials. MEDCOMM - Oncology, 2026, 5 (3) : e70089 DOI:10.1002/mog2.70089

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]

A. Yopp, M. Kudo, M. Chen, et al., “Lba39 Updated Efficacy and Safety Data From imbrave050: Phase III Study of Adjuvant Atezolizumab (Atezo) + Bevacizumab (bev) vs Active Surveillance in Patients (pts) With Resected or Ablated High-Risk Hepatocellular Carcinoma (hcc),” Annals of Oncology 35, no. Sup2 (2024): S1230.

[2]	S. Qin, M. Chen, A. L. Cheng, et al., “Atezolizumab Plus Bevacizumab Versus Active Surveillance in Patients With Resected or Ablated High-Risk Hepatocellular Carcinoma (imbrave050): A Randomised, Open-Label, Multicentre, Phase 3 Trial,” Lancet 402, no. 10415 (2023): 1835–1847.

[3]	Z. Wang, J. Fan, S. Zhou, et al., “Perioperative Camrelizumab Plus Rivoceranib Versus Surgery Alone in Patients With Resectable Hepatocellular Carcinoma at Intermediate or High Risk of Recurrence (cares-009): A Randomised Phase 2/3 Trial,” Lancet 406, no. 10515 (2025): 2089–2099.

[4]	Y. Chen and Z. Tian, “Hbv-Induced Immune Imbalance in the Development of hcc,” Frontiers in Immunology 10 (2019): 2048.

[5]	I. Martin-Padura, P. Marighetti, A. Agliano, et al., “Residual Dormant Cancer Stem-Cell Foci Are Responsible for Tumor Relapse After Antiangiogenic Metronomic Therapy in Hepatocellular Carcinoma Xenografts,” Laboratory Investigation 92, no. 7 (2012): 952–966.

Rights & permissions

2026 The Author(s). MedComm - Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).